Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Determine the best strategy for proteinuria lowering in patients with proteinuria \> 1 g/day receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of diuretic dosage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy

NCT00212901

Diabetic Kidney Disease

COMPLETED NA

Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency

NCT00630708

Renal Insufficiency, Chronic

TERMINATED NA

Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency

NCT00338091

Renal Insufficiency,Chronic Disease Progression Proteinuria +3 more

TERMINATED NA

Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination

NCT04143412

Diabetic Nephropathy Type 2 Microalbuminuria Due to Type 2 Diabetes Mellitus

UNKNOWN PHASE2

Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy

NCT01525888

Radiographic Contrast Agent Nephropathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heavy Proteinuria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ramipril 5 mg + valsartan 80 mg/day,

Intervention Type DRUG

ramipril 10 mg + valsartan 160 mg/day,

Intervention Type DRUG

ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* proteinuria \> 1 g/day with ramipril 5 + valsartan 80 mg/day for 2 months
* proteinuria changes \< 50% on 3 separate dosages over 2 months.

Exclusion Criteria

* age \< 18 or \> 80 years systolic BP \< 110 or ≥ 140 mmHg, serum creatinine \> 250 mmole/L
* serum creatinine increase on ramipril + valsartan \> 20%
* intolerance to ACEI or ARB

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No